Telmisartan and Rosuvastatin Tablets 80/10 mg
Telmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
IlYang Biopharm Co., Ltd.
MFDS item code 202101822 · Approved 2021.02.24
This product's status changed to Expired on 2026.02.24. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension and dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression
This medication is used for patients who need to take telmisartan, an antihypertensive agent, and rosuvastatin, a hyperlipidemia treatment, simultaneously. Telmisartan helps treat essential hypertension and is particularly effective in reducing the risk of myocardial infarction, stroke, and death due to cardiovascular diseases in patients at high risk. Rosuvastatin is mainly used as an adjunct to diet therapy in patients with hypercholesterolemia and dyslipidemia, specifically contributing to the delay of atherosclerosis progression by lowering LDL cholesterol and reducing cardiovascular disease risk. Additionally, there are benefits in reducing the risk of stroke, myocardial infarction, and vascular revascularization procedures in high-risk patients with elevated high-sensitivity C-reactive protein levels. Therefore, this medication is used to improve cardiovascular health in patients with both hypertension and hyperlipidemia.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg once daily by mouth as telmisartan; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg once daily by mouth. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, whereas an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience of administration.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Women of childbearing potential must use appropriate contraceptive methods before taking this medication, and it should not be used during pregnancy or breastfeeding. Patients who are allergic to any ingredients in this medication or those with severely impaired liver and kidney function or certain genetic disorders should not receive this medication. Special caution is required for the elderly, patients with hyperkalemia, and those with liver impairments, and regular monitoring of liver function and muscle status should be conducted. If symptoms like muscle pain, muscle weakness, dizziness, or severe fatigue occur, consult a physician immediately and consider stopping the medication in severe cases. This medication may interact with other drugs; thus, if you are taking other medications, you must inform your doctor or pharmacist, especially regarding blood pressure medications, diuretics, and anticoagulants. Symptoms such as hypotension, dizziness, and acute renal failure may occur in case of overdose; immediate emergency treatment should be sought. Caution is advised when driving or operating machines as dizziness or drowsiness may occur. The safety and efficacy of this medication have not been established in children, and its use is not recommended. When storing, keep it out of reach of children and do not transfer to another container.
Elevated ALT, elevated AST, elevated serum creatine phosphokinase (CPK), dizziness, itching, dyspepsia, oral paresthesia, musculoskeletal stiffness, acne, nasopharyngitis, elevated serum potassium, glycosuria, dysuria, rhinitis, pharyngeal discomfort, pulmonary disease, unspecified intestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, pharyngitis, sinusitis, urinary tract infection, cystitis, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver disorder, increased sweating, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, lumbago, muscle cramps, arthralgia, limb pain, tendon pain, acute kidney failure, chest pain, weakness, influenza-like illness, elevated serum creatinine, elevated uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, headache, facial spasms, sensory abnormalities, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, constipation, nausea, pancreatitis, hypersensitivity reactions including angioedema, diabetes, headache, itching, rash, urticaria, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, liver failure, memory decline, forgetfulness, amnestic syndrome, memory impairment, confusion, severe muscle weakness, ophthalmoplegia, headache, cough, palpitations, fatigue, nausea, lack of efficacy, myalgia, arthralgia, increased CK, numbness, sensory abnormalities, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute kidney failure, oliguria, thrombocytopenia, increased serum creatinine
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius. Doing so helps preserve the medication's effectiveness and safety over time.
Pale orange oval film-coated tablet
30 tablets/box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Telmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
IlYang Biopharm Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.